DrugPatentWatch Database Preview
Drugs in Development Information for Betadex
» See Plans and Pricing
What is the development status for investigational drug Betadex?
Betadex is an investigational drug.
There have been 9 clinical trials for Betadex.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Niemann-Pick Diseases. The leading clinical trial sponsors are Bayer, Ligand Pharmaceuticals, and Medpace, Inc.
There are two US patents protecting this investigational drug and twenty-seven international patents.
Summary for Betadex
| US Patents | 2,077 |
| International Patents | 27,215 |
| US Patent Applications | 3,219 |
| WIPO Patent Applications | 2,531 |
| Japanese Patent Applications | 37 |
| Clinical Trial Progress | Phase 3 (2016-10-01) |
| Vendors | 35 |
Recent Clinical Trials for Betadex
| Title | Sponsor | Phase |
|---|---|---|
| Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440 | Janssen Research & Development, LLC | Phase 1 |
| Adrabetadex for Patients With Nerve Symptoms of Niemann-Pick Type C Disease (NPC) | Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company | Phase 3 |
| A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe | Janssen Sciences Ireland UC | Phase 1 |
Clinical Trial Summary for Betadex
Top disease conditions for Betadex
Top clinical trial sponsors for Betadex
US Patents for Betadex
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Betadex | Start Trial | Therapeutic and imaging compositions and uses thereof | Purdue Research Foundation (West Lafayette, IN) | Start Trial |
| Betadex | Start Trial | Pharmaceutical composition for preventing or treating skin cancer comprising Panax spp. plant extract and method of preventing or treating skin cancer in a subject using the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (Seoul, KR) | Start Trial |
| Betadex | Start Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| Betadex | Start Trial | Polyurethane fiber | TORAY OPELONTEX CO., LTD. (Osaka, JP) | Start Trial |
| Betadex | Start Trial | Small molecule HSP70 inhibitors | The Trustees of the University of Pennsylvania (Philadelphia, PA) The Wistar Institute of Anatomy and Biology (Philadelphia, PA) | Start Trial |
| Betadex | Start Trial | Methods of treating of diabetes and obesity using FGF21 mutants | AMGEN INC. (Thousand Oaks, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Betadex
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Betadex | Canada | CA2911906 | 2033-05-07 | Start Trial |
| Betadex | European Patent Office | EP2994755 | 2033-05-07 | Start Trial |
| Betadex | World Intellectual Property Organization (WIPO) | WO2014182804 | 2033-05-07 | Start Trial |
| Betadex | South Korea | KR101741827 | 2035-07-10 | Start Trial |
| Betadex | South Korea | KR20170006970 | 2035-07-10 | Start Trial |
| Betadex | Australia | AU2014348657 | 2033-11-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
